Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX) have been given an average recommendation of “Moderate Buy” by the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $35.75.

Several equities research analysts recently issued reports on ODTX shares. HC Wainwright initiated coverage on shares of Odyssey Therapeutics in a research note on Thursday, August 27th. They set a “buy” rating and a $44.00 price target on the stock. Oppenheimer restated an “outperform” rating and set a $40.00 target price on shares of Odyssey Therapeutics in a research note on Thursday, June 18th. JPMorgan Chase & Co. lifted their target price on Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Zacks Research upgraded Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. Finally, Weiss Ratings started coverage on Odyssey Therapeutics in a report on Tuesday, August 11th. They issued a “sell (d+)” rating for the company.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Odyssey Therapeutics stock. The Manufacturers Life Insurance Company acquired a new position in shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 32,125 shares of the company’s stock, valued at approximately $601,000. The Manufacturers Life Insurance Company owned about 0.07% of Odyssey Therapeutics at the end of the most recent reporting period.

Odyssey Therapeutics Price Performance

Shares of ODTX opened at $23.12 on Thursday. The company has a fifty day simple moving average of $21.71. The firm has a market cap of $1.11 billion and a P/E ratio of -3.42. Odyssey Therapeutics has a fifty-two week low of $15.10 and a fifty-two week high of $29.05.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. As a group, research analysts anticipate that Odyssey Therapeutics will post -5.99 earnings per share for the current year.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, structural biology, medicinal chemistry and other drug-discovery technologies to identify therapies designed to target specific disease mechanisms.

Odyssey’s research programs are centered on small-molecule therapeutics intended to modulate immune pathways and address conditions with significant unmet medical needs.